Clinical Trial Update: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety of BIBF 1120 (nintedanib) in combination with Carboplatin and pegylated liposomal doxorubicin in patients with advanced ovar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• BIBF 1120 (nintedanib) (nintedanib)
• CARBOPLATIN (Carboplatin)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2014-11-20